Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2596-2605

  Lin, Jian Feng ^a,b   Xu, Jun ^c   Tian, Hong Yu ^b   Gao, Xia ^b   Chen, Qing Xi ^a   Gu, Qi ^b,c   Xu, Gen Jun ^b,d   Song, Jian Da ^c   Zhao, Fu Kun ^b,d  

^a XIAMEN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^d ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

2 DE; Mass spectrometry; Needle biopsy; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AMINO ACID SEQUENCE; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS;

BIOPSY, NEEDLE; CONTRACTILE PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEASIBILITY STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; MALE; MICROFILAMENT PROTEINS; NEOPLASM PROTEINS; PEROXIREDOXINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOMICS; TACROLIMUS BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 36249025664     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23016     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Yang L, Li L, Chen Y, Parkin DM. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chinese J Health Stat 2005;22:218-32.
3. Martinez M, Espana F, Royo M, Vera CD, Estelles A, Jimenez-Cruz JF, Medina P, Aznar J. Prostate-specific antigen complexed to alpha(1)- antichymotrypsin in the early detection of prostate cancer. Eur Urol 2000;38:85-90.
4. Taylor JA, III, Gancarczyk KJ, Fant GV, Mcleod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002;60:841-5.
5. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
6. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 1995;333:1401-5.
7. Jiang Z, Wu CL, Woda BA, Dresser K, Xu J, Fanger GR, Yang XJ. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002;26:1169-74.
8. Varma M, Jassani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005;47:1-16.
9. Edwards JJ, Anderson NG, Tollaksen SL, Von Eschenbach AC, Guevara J, Jr. Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer. Clin Chem 1982;28:160-3.
10. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell. Electrophoresis 2000;21:2235-42.
11. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005;27:263-72.
12. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63.
13. Ramagli LS. Quantifying protein in 2-D PAGE solubilization buffers. Methods Mol Biol 1999;112:99-103.
14. Carter HB, Isaacs WB. Improved biomarkers for prostate cancer: a definite need. J Natl Cancer Inst 2004;96:813-15.
15. Berkelman T, Stenstedt T. 2-D Electrophoresis: using Immobilized pH Gradients; Principles & Methods. Uppsala, Sweden: Amersham Biosciences, 1998.
16. Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 2000;21:3666-72.
17. Neuhoff V, Arold N, Taube D, Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988;9:255-62.
18. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-80.
19. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-105.
20. Ruddat VC, Whitman S, Klein RD, Fischer SM, Holman TR. Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. Prostate 2005;64:128-38.
21. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, Lam EW, Bevan CL. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004;23:2996-3004.
22. Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signaling. Nat Cell Biol 2004;6:1034-8.
23. Robertson SP. Filamin A: phenotypic diversity. Curr Opin Genet Dev 2005;15:301-7.
24. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 2003;63:2645-8.
25. Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA 2003;100:4562-7.
26. Hjalm G, Macleod RJ, Kifor O, Chattopadhyay N, Brown EM. Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-actrvated protein kinase. J Biol Chem 2001;276:34880-7.
27. Liu G, Thomas L, Warren RA, Enns CA, Cunningham CC, Hartwig JH, Thomas G. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. J Cell Biol 1997;139:1719-33.
28. Davies TH, Sanchez ER. FKBP52. Int J Biochem Cell Biol 2005;37:42-4.
29. Galigniana MD, Harrell JM, O'Hagen HM, Ljungman M, Pratt WB. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem 2004;279:22483-9.
30. Cheung-Flynn J, Prapapanich V, Cox MB, Riggs DL, Suarez-Quian C, Smith DF. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 2005;19:1654-66.
31. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004;10:2208-19.
32. Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000;41:1890-6.
33. Kilponen JM, Hiltunen JK. Beta-oxidation of unsaturated fatty acids in humans. Isoforms of delta 3, delta 2-enoyl-Co. A isomerase. FEBS Lett 1993;322:299-303.
34. Janssen U, Davis EM, Le Beau MM, Stoffel W. Human mitochondrial enoyl-CoA hydratase gene (ECHS1): structural organization and assignment to chromosome 10q26.2-q26.3. Genomics 1997;40:470-5.
35. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, Kang KR, Hyun JS, Chung KH. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 2005;20:450-5.
36. Yokoyama Y, Kuramitsu Y, Takashima M, Iizuka N, Toda T, Terai S, Sakaida I, Oka M, Nakamura K, Okita K. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 2004;4:2111-16.
37. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2005;63:316-23.
38. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003;28:32-40.
39. Butterfield LH, Merino A, Golub SH, Shau H. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal 1999;1:385-402.
40. Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK, Kwon OY, Kim YK, Ro HK, Shong M. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 2000;275:18266-70.
41. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002;196:316-23.
42. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 2006;175:1512-16.
43. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003;9:3418-24.
44. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 2004;14:491-9.
45. Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000;21:1218-26.
46. Gibbons NB, Watson RW, Coffey RN, Brady HP, Fitzpatrick JM. Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 2000;45:58-65.
47. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602.